Alumis (ALMS)

The company’s lead programme is envudeucitinib, also referred to as envu, an allosteric TYK2 inhibitor being evaluated for conditions including plaque psoriasis and systemic lupus erythematosus. Allosteric TYK2 inhibition is intended to modulate inflammatory signalling while aiming for selectivity versus other Janus kinase family members, an important consideration in a therapeutic area where safety and long-term tolerability are central to commercial adoption.

Alumis is also advancing A-005, a TYK2 inhibitor designed to penetrate the central nervous system. That programme extends the company’s immunology platform into neuroinflammatory and neurodegenerative disease research, where immune signalling inside the brain and spinal cord is an area of growing scientific interest. The potential applications are broad, but development remains early and subject to the normal uncertainty of clinical biotechnology.

As a listed biopharmaceutical company, Alumis does not resemble a mature healthcare business with diversified product revenue. Its investment profile is shaped by pipeline execution, cash runway, study design, partnership potential, and the ability to differentiate its candidates from approved and emerging therapies targeting similar pathways.